Clinical Trials Logo

Sarcoidosis clinical trials

View clinical trials related to Sarcoidosis.

Filter by:

NCT ID: NCT05421975 Recruiting - Sarcoidosis Clinical Trials

Evaluating Airway Sarcoidosis Pathology With MRI

EASY MRI
Start date: June 28, 2021
Phase:
Study type: Observational

Sarcoidosis is a condition where inflamed cells clump together to form granulomas, which can lead to inflammation or scarring. It can affect any organ of the body, but most commonly affects the lungs. Symptoms can be highly variable, and some patients have no symptoms where as others may develop fatigue or breathlessness. The causes of sarcoidosis are poorly understood. It commonly affects adults in their 30's or 40's. Some patients present with symptoms suggestive of involvement in the airways, such as cough. Inhalers containing steroid are commonly used, but there is a poor understanding of which patients may benefit. Part of the problem is the lack of a sensitive way of measuring these effects and knowledge of how sarcoidosis affects the airways physiologically. The investigators would like to know more about the disease process of sarcoidosis, particularly where it involves the airways. This study will use a number of techniques in order to better understand to disease process. In order to assess whether sarcoidosis produces changes in airway ventilation (and whether these changes are stable or change over a short time period). This pilot study aims to recruit 6 patients who will have magnetic resonance imaging (MRI) with inhaled xenon gas. During this technique, xenon and nitrogen mixture is inhaled and during a subsequent breath-hold, images of the lungs are taken. This creates a detailed view of the lung airway tree, to explore how the disease affects the airways and deeper lung tissue. This technique will be used alongside lung function tests, commonly performed in the laboratory setting and cardiopulmonary exercise testing, to see what happens in the lungs of this group of patients when they reach peak exercise capacity.

NCT ID: NCT05415137 Recruiting - Clinical trials for Pulmonary Sarcoidosis

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Start date: September 15, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.

NCT ID: NCT05392881 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease Research Unit Biobank

ILDRU
Start date: August 9, 2021
Phase:
Study type: Observational [Patient Registry]

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

NCT ID: NCT05374447 Recruiting - Clinical trials for Sarcoidosis, Pulmonary

Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

Start date: June 10, 2022
Phase: N/A
Study type: Interventional

The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.

NCT ID: NCT05368883 Active, not recruiting - Clinical trials for Pulmonary Sarcoidosis

Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Pulmonary rehabilitation is a key element in the management of people with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue can also be associated with sarcoidosis for different reasons. Individualized rehabilitation training can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use, in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters.

NCT ID: NCT05351554 Terminated - Clinical trials for Sarcoidosis, Cardiac

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

RESOLVE-Heart
Start date: August 23, 2022
Phase: Phase 2
Study type: Interventional

A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.

NCT ID: NCT05314517 Active, not recruiting - Clinical trials for Sarcoidosis, Pulmonary

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

RESOLVE-Lung
Start date: August 31, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

NCT ID: NCT05311150 Completed - Clinical trials for Sarcoidosis, Pulmonary

An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis

NABS
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

In the diagnosis of patients with sarcoidosis, there is paucity of literature on the diagnostic yield of the endobronchial biopsies obtained with narrow band imaging (NBI) bronchoscopy. The present study aims to compare the diagnostic yield of endobronchial biopsyperformed under direct narrow band imaging or white light bronchoscopy guidance in suspected sarcoidosis.We hypothesize that the use of NBI will improve the yield of endobronchial biopsy in patients with sarcoidosis.

NCT ID: NCT05291468 Not yet recruiting - Clinical trials for Sarcoidosis, Pulmonary

the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

In this study it is investigated whether treatment with azithromycin in combination with doxycycline reduces the bacterial load of C. acnes in granulomatous tissue of patients with sarcoidosis and subsequently decreases the inflammatory activation measured by FDG uptake and serum biomarkers.

NCT ID: NCT05247554 Not yet recruiting - Clinical trials for Pulmonary Sarcoidosis

Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis

QUIDOSE
Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

"The reference treatment for pulmonary sarcoidosis is prolonged systemic corticosteroid therapy, which improves dyspnea, fatigue and respiratory function. However, corticosteroid therapy doesn't improve quality of life, possibly due to its adverse effects. Furthermore, in an international survey study, the first priority in treatment outcome for sarcoidosis patient was quality of life. Hydroxychloroquine an antimalarial drug, has been shown to be effective in cutaneous and pulmonary forms of sarcoidosis but in studies with imperfect methodology. Our hypothesis is that hydroxychloroquine associated with low-dose corticosteroids improves lung function as much as ""conventional"" medium-dose corticosteroid therapy but with fewer side effects and a better quality of life in pulmonary sarcoidosis. "